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Abstract
Background: The management of breakthrough pain in cancer patients is always a challenge for medical professions.
Occurring in 80% of cancer patients with advanced disease, breakthrough pain significantly decreases both patient’s
and caregiver’s quality of life. The aim of this study is to assess the analgesic efficacy of a fixed inhaled nitrous oxide/
oxygen mixture for adult cancer patients with breakthrough pain.
Methods/design: This is a randomized, placebo-controlled, double-blind study; it will be conducted in the General
Hospital of Ningxia Medical University. The target study subjects are at least 18 years old, and are hospitalized cancer
patients who are receiving routine opioids to control cancer-related pain but still experience breakthrough pain. A total
of 240 patients will be recruited and randomly allocated between three treatment groups (A, B, C) and a control group
(group D) in a ratio of 3:1. All treatment groups (A, B, C) will receive standard pain treatment (oral immediate-release
morphine) plus a pre-prepared nitrous oxide/oxygen mixture, and the control group (D) will receive the standard pain
treatment plus oxygen. Patients, doctors, nurses, and data collectors are all blind to the experiment. Assessments will
be taken before treatment (T0), at 5 min (T1) and 15 min (T2) during treatment, and at 5 min after treatment (T3). The
primary endpoint measures will be the percentage of patients whose pain is relieved at T1, T2, and T3. Secondary
outcome measures will include the safety of treatment, adverse events, and satisfaction from both health professionals
and patients.
Discussion: This study aims to provide an effective and practical intervention for a fast breakthrough pain relief and to
improve cancer patients’ quality of life significantly. The Evidence-Based Medicine Working Group claim that a
randomized, double-blind, placebo-controlled experimental intervention is the most appropriate design to
demonstrate its efficacy, so this study could give a new approach to controlling breakthrough pain episodes.
Trial registration: ChiCTR-INC-16008075. Registered on 8 March 2016.
Keywords: Analgesia, Breakthrough pain, Cancer patients, Nitrous oxide
* Correspondence: li_yuxiang@163.com; yujq910315@163.com
†Equal contributors
1School of Nursing, Ningxia Medical University, 1160 Sheng Li Street,
Yinchuan 750004, China
5Department of Pharmacology, Pharmaceutical Institute of Ningxia Medical
University, 1160 Sheng Li Street, Yinchuan 750004, China
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Liu et al. Trials  (2017) 18:13 
DOI 10.1186/s13063-016-1739-9
Background
In 2015, there were approximately 15 million newly diag-
nosed cancer cases in the world and about 4.3 million new
cases in China alone [1, 2]. Cancer pain is common. The
estimated prevalence of cancer-related pain is 30–50% for
those who are under chronic pain treatment; over 80% of
those with advanced disease suffer moderate to severe pain
[3]. Most cancer pain is chronic and caused by the tumor.
About 50–90% of patients reported intermittent flaring of
pain [4] with a 30–40% rate during the early stages of the
disease and 70–90% during advanced stages [5].
Cancer pain is classified as background pain or
breakthrough pain according to its temporal characteristics
[6, 7]. Background pain, also known as chronic persistent
pain, refers to a constant or continuous pain that lasts for
more than 12 hours per day [6]. Breakthrough pain is a
negative prognostic indicator for pain control. The Associ-
ation for Palliative Medicine of Great Britain and Ireland
task group defines breakthrough pain as a transitory in-
crease in pain intensity that occurs either spontaneously or
in relation to a specific predictable or unpredictable trigger
despite the use of long-term and around-the-clock analge-
sics to control background pain. With this definition, break-
through pain includes both spontaneous (idiopathic) and
incidental (precipitated) pain. Spontaneous pain is unpre-
dictable. Incidental pain is somewhat predictable and
usually categorized into three sub-types: volitional, non-
volitional, and procedural [6–13]. More than 50% of
breakthrough pain is reported to be spontaneous [13].
Both inter-individual and intra-individual breakthrough
pain varies in terms of timing and severity [6]. A typical
breakthrough pain episode is characterized by a rapid onset
(median interval of 3 min to peak pain) [14], moderate to
severe in intensity (numerical pain rating scale > 4), short
duration (median 30–60 minutes) [14], and self-limited
(median number of 4 (times) episodes per day with a range
of 1-14) [8, 15]. Patients with breakthrough pain have sig-
nificantly greater pain-related functional impairment [3, 16]
and decreased satisfaction with their analgesic therapy [6];
these are correlated with increased suicidal thoughts [17].
The unrelieved breakthrough pain increases patients’ psy-
chological distress and susceptibility to such illnesses as de-
pression and anxiety [3, 18], which put a negative impact
on quality of life [3, 6, 19]. It also lays an additional eco-
nomic burden on the healthcare system because it increases
emergency outpatient visits, hospital admissions, and hos-
pital stay [20–22].
The World Health Organization three-step analgesia lad-
der can manage about 80% of background pain with simple
interventions [5, 15]. However, the sudden onset, severity,
and short duration of breakthrough pain make its manage-
ment more difficult [15]. Traditionally, breakthrough pain
is managed by varying oral immediate-release opioid at 5–
15% [23], 10–20% [24], or one-sixth of the total daily opioid
dosage [14]. However, in most cases, the pharmacokinetic
and pharmacodynamic profiles of such oral opioids do not
align with the rapid nature of breakthrough pain [25–27].
Several studies indicated that the average onset of action
for oral opioid (including morphine, oxycodone, and hydro-
morphone) as rescue medications among hospice patients
was greater than 30 min [28, 29]. This long onset of action
means that the oral immediate-release opioids are not ideal
rescue medications for most breakthrough pain. Studies
have evaluated the effectiveness of transmucosal fentanyl
formulations for breakthrough pain management [29]. As
oral or nasal mucosa allows a more rapid absorption and
avoids the first-pass metabolism, transmucosal fentanyl’s
onset of action is within 10–15 min after administration
[29, 30]. However, some research suggested that the oral
transmucosal fentanyl citrate showed a negative correlation
with a fixed-schedule opioid regimen and patients have to
undergo up to 26 days of the dose-titration phase to deter-
mine the optimal dose [31, 32]. Another drawback for this
preparation is its high cost. Intravenous morphine is an-
other agent that, at 20% of its basal oral dosage, is a fast,
safe, and highly effective option for the relief of break-
through pain. Its onset of action starts in 3 min and peaks
at 10 min [33], but this invasive route of administration and
the lack of breakthrough pain management guidelines
made this approach less favorable.
A self-administered inhaled nitrous oxide/oxygen mix-
ture is available in pre-prepared cylinders. It has been used
in various types of pain management, including labor [34],
dental procedures [35], trauma [36], burn dressing [37],
surgical procedures, and other medical conditions. The ni-
trous oxide/oxygen mixture has potent analgesic proper-
ties but does not cause loss of consciousness. This gas is
safe, noninvasive, and an effective form of pain relief,
owing to its low blood/gas solubility ratio, which allows
for rapid onset (1–2 min) and short duration of action
(35–45 s) after discontinuation [38, 39]. The absorbed gas
is also readily excreted unchanged mainly through the
lungs [40, 41]. The administration of nitrous oxide/oxygen
mixture is easy to control. Its side effects is generally dis-
appear quickly after the termination of exposure to the
gas [40, 41].
In mainland China, transmucosal fentanyl prepara-
tions are not available and have not been used to
control breakthrough pain [data from Chinese Mar-
keted Drugs Database]. According to anesthetists, oral
immediate-release opioid is the first choice in control-
ling breakthrough pain in China. However, with its
slow onset of action (20–30 min; peak > 45 min) [42],
it delays pain relief and reduces patients’ compliance.
Studies by Li et al. showed that a fixed diluted ni-
trous oxide/oxygen mixture would provide a sufficient
analgesic effect during the burn-dressing procedure;
patients reported the most satisfaction for this
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method [17, 37]. However, to our knowledge, there
are no studies on the use of nitrous oxide/oxygen
mixture to treat breakthrough pain yet. We
hypothesize that a nitrous oxide/oxygen mixture can
provide the same analgesic effect for cancer patients
within breakthrough pain episodes. This is a nurse-
led, patient-participate, randomized controlled trial.
This article describes the study background, design,
treatment administration, and data analysis approach.
Methods
Study design
This study is a randomized, double-blind, placebo-
controlled, parallel clinical trial to test the analgesic
efficacy of a fixed inhaled nitrous oxide/oxygen mix-
ture on adult cancer patients with breakthrough pain.
This article has been drafted following SPIRIT
guidelines [43] (see Additional file 1). Patients in the
treatment groups will receive standard pain treatment
plus pre-prepared nitrous oxide/oxygen mixture and
patients in the control group will receive standard
pain treatment plus oxygen when they report a
breakthrough pain episode. The study protocol will
use the Consolidated Standards of Reporting Trials
(CONSORT) [44] statement recommendations (see
Additional file 2). The overall trial design is provided
in Fig. 1. Furthermore, the schedule of enrolment, in-
terventions, and assessments are presented in Table 1.
The stratification factors were not contemplated in
this study. breakthrough pain is a transitory
exacerbation of pain that occurs despite the use of
long-term and around-the-clock analgesics to control
persistent pain, and there is no nature differences in
two types of breakthrough pain. So we did not make
stratification analyses in this study.
Participants
All cancer patients from the oncology ward who have
breakthrough pain will be invited to participate. Da-
vies’ Adapted Diagnostic Algorithm will be used to
screen patients for the presence of breakthrough pain
[8]. The main inclusion criteria are: Chinese-speaking
patients older than 18 years; recent worst pain (break-
through pain) reported to be 4 or higher on a numer-
ical pain rating scale of 0 to 10; a score on the
Karnofsky Performance Status Scale above 20; and
ability to take deep breaths in order to use the self-
administered device. Patients will be excluded if they
have a known contraindication to the use of nitrous
oxide or have impaired cognitive function. Specific
inclusion and exclusion criteria are presented in
Table 2.
Treatments
Eligible patients will receive oral immediate-release mor-
phine with a proportion of 10–20% daily total doses of oral
morphine as the standard breakthrough pain treatment
[24]. Patients will be instructed to use of study apparatus,
which provides a fix concentration of nitrous oxide/oxygen
mixture or oxygen to a disposable, demand valve, scented
oral–nasal mask. Patients will hold the mask, which is
opened by the negative pressure of patients to control the
gas taken in. The experimental group will receive a fixed
concentration of nitrous oxide/oxygen mixture and the
control group will receive oxygen during breakthrough pain
episodes. Gas inhalation will be administered until the
breakthrough pain episode is over. The project manager is
in charge of assignment, allocation, and treatment delivery.
All gas cylinders used in both two groups are identical in
appearance. The patients, nurse, and data collector are all
blind to the treatment.
Randomization, allocation concealment, and binding
Owing to the severity of the pain, ethicists suggest helping
as many suffering patients as possible. In total, 240 partici-
pants will be randomized into four groups in a ratio of 3:1;
three treatment groups (A, B, C), n = 180, and one control
group (D), n = 60. The allocation sequence of each patient
is decided by a computer-generated schedule, which is
numbered by a statistician. The randomization schedule
will be kept and sealed in an independent research room.
Apart from the project manager, who is responsible for
gas distribution, no other nurses or data collectors will
have access to the data allocation. The nurse is blind to
the double-blind randomized controlled trial lists (see
Additional file 3) because the list does not indicate what
treatment letters A, B, C, and D stand for.
Measurement
Patient’s demographic data (age, sex, nationality, height,
weight), cancer diagnosis, baseline breakthrough pain in-
tensity, current background pain opioid medication dos-
age, duration of nitrous oxide/oxygen mixture use, dosage
of oral rescue morphine medication, and any side or ad-
verse effects of nitrous oxide/oxygen mixture treatment
will be recorded by researchers [45]. A numerical pain rat-
ing scale (range from 0 to 10) is used to assess for pain in-
tensity along with heart rate, noninvasive monitoring of
blood pressure, and digitally monitored oxygen saturation
at baseline (T0 before treatment), 5 min (T1) and 15 min
(T2) after the beginning of treatment, and at 5 min (T3)
after treatment finished. Heart rate, blood pressure, and
oxygen saturation will be monitored by Infinity® Delta XL
(Draeger Medial Systems Inc., Danvers, Shanghai, China).
A five-point satisfaction scale (5, very satisfied; 4, satisfied;
3, uncertain; 2, dissatisfied; 1, very dissatisfied) will be used
to assess both patients’ and healthcare professionals’
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5 min after starting
intervention (T1)
15 min after starting
intervention (T2)







Control group √ √




√ √ √ √
Blood pressure √ √ √ √
Oxygen
saturation
√ √ √ √
Heart rate √ √ √ √
Satisfaction √
Side effect √ √ √
Fig. 1 Study design framework. BP, blood pressure; BTP, breakthrough pain; HR, heart rate; NOOM, nitrous oxide/oxygen mixture: NRS, numerical
pain rating scale; SPO2, oxygen saturation; STN, standard treatment with nitrous oxide/oxygen mixture; STO, standard treatment with oxygen
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satisfaction with breakthrough pain treatment [46]. Any
side effects of the nitrous oxide/oxygen mixture treat-
ment, such as nausea, vomiting, dizziness, drowsiness,
and headache [17], will be carefully monitored by re-
searchers after the initiation of the gases inhalation.
Endpoints
Primary endpoint measures
The primary endpoint measures will be the percentage
of patients receiving pain relief at T1, T2, and T3.
Repeated-measures analysis of variance will be used for
data analysis.
Secondary endpoint measures
Secondary outcome measures will include treatment safety,
adverse events, and satisfaction from both health profes-
sionals and patients. The total time of nitrous oxide/oxygen
mixture administration will be also recorded.
Sample size determination
According to our previous study on burn-dressing
pain [17, 37], we used preliminary observational data
obtained in medical oncology for 20 patients. We
found that 90% of patients receiving pre-prepared ni-
trous oxide/oxygen mixture experienced pain relief (a
decrease of at least 30% in pain intensity [47]) at 15
min versus 10% of patients in the control group. The
aim of this study is to assess the efficacy of the ni-
trous oxide/oxygen mixture, so a sample size of 12
was targeted with a two-tail test with type-1 error
rate of 0.05 and a power of 90% to be sufficient. We
decided on a sample size of 240 to meet the Chinese
Food and Drug Administration standard for feasibility
and the safety of nursing staff in implementing this
analgesic [17].
Data management and analysis
Before the study, all data collectors will be trained in
the data collection procedure. Data from withdrawn
patients will not be used in the final analysis. SPSS
version 22.0 (SPSS Inc., IBM Company, Chicago, IL,
USA) will be used to conduct quantitative analysis
following the intention-to-treat principle for a case-
control randomized trial. Descriptive statistics will be
analyzed by medians (inter-quartile ranges), means
(standard deviations), and proportions (exact binomial
95% confidence intervals), as appropriate. Proportions
will be compared by using the chi squared test or the
Fisher’s exact test. Means will be compared using Stu-
dent’s t test (normal distribution parameters) or a
nonparametric two-sample Mann–Whitney test (non-
normal distribution parameters). Statistical signifi-
cance will be considered for P < 0.05.
Discussion
Many studies on transmucosal fentanyl showed excellent
breakthrough pain reduction after 15 min administration
[11, 23, 30, 48]. But that means patients have to suffer for
at least 15 minutes severe pain. Furthermore, this fentanyl
preparation is unavailable in China. In addition to the
incompliance and adverse effects of oral immediate-release
morphine, many other opioid formulations also appeared
incapable of effectively relieving breakthrough pain due to
their slow onset of actions (15–60 minutes) [11, 23, 30, 48].
This study intends to find a better alternative rescue medi-
cation for cancer patients with breakthrough pain in China.
The study of Li et al. on burns-dressing procedure
pain showed faster pain reduction, within 15–20 s, for
the pre-prepared nitrous oxide/oxygen mixture group
[17, 37]. However, another study found that inhaled ni-
trous oxide showed a non-significant reduction in pain
scores in metastatic dying patients with cancer-related
incident pain [49]. In this study, we will attempt to verify
both the analgesic efficacy of the fixed nitrous oxide/
oxygen mixture, and patients’ and healthcare workers’
satisfaction in using the nitrous oxide/oxygen mixture
for breakthrough pain management.
To our knowledge, this study is the first randomized
controlled trial to evaluate the effectiveness of the pre-
prepared nitrous oxide/oxygen mixture to treat break-
through pain in cancer patients with advanced disease. If
this treatment appears beneficial, this study can help to
generate preliminary guidelines on breakthrough pain
management in cancer patients with advanced disease. We
intend to disseminate the results of this study to inter-
national journals and conferences.
Trial status
Patient recruitment will start on 24 July 2016.
Table 2 Inclusion and exclusion criteria
Inclusion criteria
Patient aged 18 years or older
Patient experiencing breakthrough pain episode with a stable dose of
opioids to control background pain
Written informed consent for participation obtained prior to any
study procedures
Exclusion criteria
Patient with mental disorder, altered mental status
Patient has difficulty in reporting pain
Karnofsky Performance Status Scale score under 20
Abdominal distension or suspected bowel obstruction, air embolism,
pneumothorax, decompression sickness, epilepsy, pulmonary cancer,
chronic obstructive pulmonary disease and acute respiratory infection,
pregnancy, severe inhalation injury; pharmaceutical or pathological
pulmonary fibrosis; maxillofacial injuries
Disease involving ear, nose, larynges, such as sinuses, middle ear
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